Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension

Human Mutation

Volumn 32, Issue 12, 2011, Pages 1385-1389

  Nasim, Md Talat ^a   Ogo, Takeshi ^a   Ahmed, Mohammad ^a   Randall, Rebecca ^a   Chowdhury, Hasnin M ^a   Snape, Katie M ^a   Bradshaw, Teisha Y ^a   Southgate, Laura ^a   Lee, Grace J ^a   Jackson, Ian ^b   Lord, Graham M ^b   Gibbs, J Simon R ^c   Wilkins, Martin R ^d   Ohta Ogo, Keiko ^e   Nakamura, Kazufumi ^e   Girerd, Barbara ^f   Coulet, Florence ^g   Soubrier, Florent ^g   Humbert, Marc ^f   Morrell, Nicholas W ^h   Trembath, Richard C ^a   Machado, Rajiv D ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d Science and Technology   (United Kingdom)

^e OKAYAMA UNIVERSITY   (Japan)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BMPR2; Pulmonary hypertension; SMAD4; Transcriptional regulation

Indexed keywords

BONE MORPHOGENETIC PROTEIN; MUTANT PROTEIN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; MOLECULAR GENETICS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; MALE; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD8 PROTEIN;

EID: 81255136932     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21605     Document Type: Article

References (17)

1. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. 2000. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737-744.
2. Gallione CJ, Richards JA, Letteboer TG, Rushlow D, Prigoda NL, Leedom TP, Ganguly A, Castells A, Ploos van Amstel JK, Westermann CJ, Pyeritz RE, Marchuk DA. 2006. SMAD4 mutations found in unselected HHT patients. J Med Genet 43:793-797.
3. Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, Aldred MA, Trembath RC. 2005. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111:435-441.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G. 2010. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156-163.
5. Ishida W, Hamamoto T, Kusanagi K, Yagi K, Kawabata M, Takehara K, Sampath TK, Kato M, Miyazono K. 2000. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J Biol Chem 275:6075-6079.
6. Iyer NK, Burke CA, Leach BH, Parambil JG. 2010. SMAD4 mutation and the combined syndrome of juvenile polyposis syndrome and hereditary haemorrhagic telangiectasia. Thorax 65:745-746.
7. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, 3rd, Loyd JE, Nichols WC, Trembath RC. 2000. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26:81-84.
8. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA, 3rd, Soubrier F, Trembath RC, Chung WK. 2009. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 54:S32-S42.
9. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA, 3rd, Newman J, Williams D, Galie N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC. 2001. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68:92-102.
10. Massague J, Blain SW, Lo RS. 2000. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295-309.
11. Nalla VK, Rogan PK. 2005. Automated splicing mutation analysis by information theory. Hum Mutat 25:334-342.
12. Nasim MT, Chowdhury HM, Eperon IC. 2002. A double reporter assay for detecting changes in the ratio of spliced and unspliced mRNA in mammalian cells. Nucleic Acids Res 30:e109.
13. Nasim MT, Ghouri A, Patel B, James V, Rudarakanchana N, Morrell NW, Trembath RC. 2008. Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertension. Hum Mol Genet 17:1683-1694.
14. Nishihara A, Watabe T, Imamura T, Miyazono K. 2002. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 13:3055-3063.
15. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. 2002. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 11:1517-1525.
16. Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. 2009. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 46:331-337.
17. Southgate L, Machado RD, Snape KM, Primeau M, Dafou D, Ruddy DM, Branney PA, Fisher M, Lee GJ, Simpson MA, He Y, Bradshaw TY, Blaumeiser B, Winship WS, Reardon W, Maher ER, Fitzpatrick DR, Wuyts W, Zenker M, Lamarche-Vane N, Trembath RC. 2011. Gain-of-function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia and limb anomalies. Am J Hum Genet88:574-585.